94 related articles for article (PubMed ID: 12040360)
1. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
Langleben D; Christman BW; Barst RJ; Dias VC; Galiè N; Higenbottam TW; Kneussl M; Korducki L; Naeije R; Riedel A; Simonneau G; Hirsch AM; Rich S; Robbins IM; Oudiz R; McGoon MD; Badesch DB; Levy RD; Mehta S; Seeger W; Solèr M
Am Heart J; 2002 May; 143(5):E4. PubMed ID: 12040360
[TBL] [Abstract][Full Text] [Related]
2. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer.
Muck S; Weber AA; Schrör K
Eur J Pharmacol; 1998 Feb; 344(1):45-8. PubMed ID: 9570446
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects.
Guth BD; Narjes H; Schubert HD; Tanswell P; Riedel A; Nehmiz G
Br J Clin Pharmacol; 2004 Jul; 58(1):40-51. PubMed ID: 15206991
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane synthetase inhibition in primary pulmonary hypertension.
Rich S; Hart K; Kieras K; Brundage BH
Chest; 1987 Mar; 91(3):356-60. PubMed ID: 3545698
[TBL] [Abstract][Full Text] [Related]
5. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
6. Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Norberg B; Dogné JM; Durant F; Masereel B; Delarge J; Wouters J
Acta Crystallogr C; 2000 Oct; 56 ( Pt 10)():1265-6. PubMed ID: 11025320
[TBL] [Abstract][Full Text] [Related]
7. Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets.
Fike CD; Zhang Y; Kaplowitz MR
J Appl Physiol (1985); 2005 Aug; 99(2):670-6. PubMed ID: 15802364
[TBL] [Abstract][Full Text] [Related]
8. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
9. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Rolin S; Dogné JM; Durant F; Masereel B; Delarge J; Wouters J
Bioorg Med Chem Lett; 2001 Apr; 11(8):1019-22. PubMed ID: 11327579
[TBL] [Abstract][Full Text] [Related]
10. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
11. Emerging medical therapies for pulmonary arterial hypertension.
Galiè N; Manes A; Branzi A
Prog Cardiovasc Dis; 2002; 45(3):213-24. PubMed ID: 12525997
[TBL] [Abstract][Full Text] [Related]
12. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor.
Imura Y; Terashita Z; Shibouta Y; Nishikawa K
Eur J Pharmacol; 1988 Mar; 147(3):359-65. PubMed ID: 2967770
[TBL] [Abstract][Full Text] [Related]
13. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
14. The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin.
Fontana P; Alberts P; Sakariassen KS; Bounameaux H; Meyer JP; Santana Sorensen A
J Thromb Haemost; 2011 Oct; 9(10):2109-11. PubMed ID: 21777369
[No Abstract] [Full Text] [Related]
15. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
Heinisch G; Holzer W; Kunz F; Langer T; Lukavsky P; Pechlaner C; Weissenberger H
J Med Chem; 1996 Sep; 39(20):4058-64. PubMed ID: 8831771
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
17. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
[TBL] [Abstract][Full Text] [Related]
18. Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery.
Kim YD; Foegh ML; Wallace RB; Ng L; Ahmed SW; Katz NM; Siegelman R; Franco K; Douglas F; Ku E
Circulation; 1988 Sep; 78(3 Pt 2):I44-50. PubMed ID: 3409518
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
Dickinson RP; Dack KN; Long CJ; Steele J
J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
